These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 3953428)

  • 21. Treatment of resistant hypertension: 3 years of follow-up with the combination of verapamil and methyldopa.
    Spritzer N; Spritzer TS; Rodrigues R
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S65-7. PubMed ID: 2475692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension.
    Muijsers RB; Curran MP; Perry CM
    Drugs; 2002; 62(17):2539-67. PubMed ID: 12421112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum concentration and antihypertensive effect of slow-release verapamil.
    Schütz E; Ha HR; Bühler FR; Follath F
    J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S346-9. PubMed ID: 6184566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationships between verapamil plasma concentrations and its antihypertensive action.
    Gonzalez-Gomez A; Cires Pujols M; Gamio Capestany F; Rodriguez de la Vega A; Garcia-Barreto D
    Int J Clin Pharmacol Ther Toxicol; 1988 Sep; 26(9):453-60. PubMed ID: 3198301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of intravenous verapamil administration on left ventricular diastolic function in systemic hypertension.
    Betocchi S; Cuocolo A; Pace L; Chiariello M; Trimarco B; Alfano B; Ricciardelli B; Salvatore M; Condorelli M
    Am J Cardiol; 1987 Mar; 59(6):624-9. PubMed ID: 3825903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Once a day verapamil in essential hypertension.
    Müller FB; Ha HR; Hotz H; Schmidlin O; Follath F; Bühler FR
    Br J Clin Pharmacol; 1986; 21 Suppl 2(Suppl 2):143S-147S. PubMed ID: 3530298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twice-daily administration of oral verapamil in the treatment of essential hypertension.
    Frishman W; Charlap S; Kimmel B; Saltzberg S; Stroh J; Weinberg P; Monuszko E; Wiezner J; Dorsa F; Pollack S
    Arch Intern Med; 1986 Mar; 146(3):561-5. PubMed ID: 3954530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arterial baroreceptor resetting in hypertension (the J. W. McCubbin memorial lecture).
    Krieger EM
    Clin Exp Pharmacol Physiol Suppl; 1989; 15():3-17. PubMed ID: 2680187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The effects of slow-release verapamil in relation to plasma concentration in aged hypertensives. A study with continuous monitoring of arterial pressure and electrocardiogram].
    Canonico V; Bonaduce D; De Caprio L; Nicolino A; Forgione L; Petretta M; Rengo F
    G Ital Cardiol; 1990 Oct; 20(10):924-32. PubMed ID: 2090531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The antihypertensive effect of verapamil at extremes of dietary sodium intake.
    Nicholson JP; Resnick LM; Laragh JH
    Ann Intern Med; 1987 Sep; 107(3):329-34. PubMed ID: 3619222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study).
    Brunner M; Cooper-DeHoff RM; Gong Y; Karnes JH; Langaee TY; Pepine CJ; Johnson JA;
    Am J Cardiol; 2007 Jun; 99(11):1549-54. PubMed ID: 17531579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of sustained-release verapamil: automatic ambulatory blood pressure monitoring.
    Zachariah PK; Sheps SG; Schriger A
    J Clin Hypertens; 1986 Sep; 2(3 Suppl):133S-142S. PubMed ID: 3540223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients.
    Chrysant SG; Fox AA; Stimpel M
    Am J Hypertens; 1995 Apr; 8(4 Pt 1):418-21. PubMed ID: 7619356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of enalapril and sustained-release verapamil in older patients with mild to moderate essential hypertension.
    Weir MR; Cassidy CA; Hall PS; Lancaster A; Schubert C; Urick A; Saunders E; Kong BW; Jenkins P; Lavin PT
    Clin Ther; 1990; 12(2):139-48. PubMed ID: 2354483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipid profile during antihypertensive treatment. The SLIP Study Group. Study on Lipids with Isoptin Press.
    Libretti A; Catalano M
    Drugs; 1993; 46 Suppl 2():16-23. PubMed ID: 7512469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conversion from sustained-release to immediate-release calcium entry blockers: outcome in patients with mild-to-moderate hypertension.
    Hilleman DE; Mohiuddin SM; Lucas BD; Shinn B; Elsasser GN
    Clin Ther; 1993; 15(6):1002-10. PubMed ID: 8111798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antihypertensive efficacy of sustained-release verapamil.
    Zachariah PK; Sheps SG; Oshrain C; Schirger A; Stein WJ
    J Clin Hypertens; 1987 Dec; 3(4):536-46. PubMed ID: 3330987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Verapamil infusion in hypertension.
    Bhat RP; Wasir HS
    Indian Heart J; 1982; 34(4):228-31. PubMed ID: 7141451
    [No Abstract]   [Full Text] [Related]  

  • 39. Sustained-release verapamil as a first-step drug in the treatment of mild to moderate hypertension.
    Karcier SM; Orbay B; Ozder AB; Gürses N; Aytekin S; Satar S; Oztürk M; Demiroğlu C
    J Int Med Res; 1989; 17(3):268-76. PubMed ID: 2767329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of sustained-release Verapamil on the morning systemic arterial pressure surge during daily activity in patients with systemic hypertension.
    Rosito GA; Gebara OC; McKenna CA; Solomon HS; Muller JE; Tofler GH
    Am J Cardiol; 1997 May; 79(9):1252-5. PubMed ID: 9164897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.